Stroke risk in patients with nonvalvular atrial fibrillation increases markedly with age. Although anticoagulation is more effective than antiplatelet therapy in atrial fibrillation, it tends to be underutilized in the elderly. A study by van Walraven et al. examines the influence of age on stroke prevention therapy in atrial fibrillation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983–988 (1991).
van Walraven, C. et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40, 1410–1416 (2009).
Gladstone, D. J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40, 235–240 (2009).
Hylek, E. M., Frison, L., Henault, L. E. & Cupples, A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 39, 3009–3014 (2008).
Schwarz, U. I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999–1008 (2008).
Humphries, K. H. et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can. J. Cardiol. 20, 869–876 (2004).
Caplan, L. R. & Fisher, M. The endothelium, platelets, and brain ischemia. Rev. Neurol. Dis. 4, 113–121 (2007).
Andres, E. et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 171, 251–259 (2004).
Spence, J. D. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 7, 830–838 (2007).
Eriksson, B. I., Quinlan, D. J. & Weitz, J. I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin. Pharmacokinet. 48, 1–22 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J. David Spence is a consultant for Novartis and has been on the speaker's bureau/honoraria for Pfizer, Novartis, Merck Schering, Astra Zeneca and Boehringer Ingelheim.
Rights and permissions
About this article
Cite this article
Spence, J. Atrial fibrillation, stroke prevention therapy and aging. Nat Rev Cardiol 6, 448–450 (2009). https://doi.org/10.1038/nrcardio.2009.98
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.98
This article is cited by
-
Atrial fibrillation and stroke prevention: is warfarin still an option? Yes
Journal of Neural Transmission (2013)
-
Atrial electromechanical coupling interval and P-wave dispersion in healthy elderly
Aging Clinical and Experimental Research (2012)
-
Secondary stroke prevention
Nature Reviews Neurology (2010)
-
Neuroprotective effect of combined hypoxia-induced VEGF and bone marrow-derived mesenchymal stem cell treatment
Child's Nervous System (2010)